Successful Treatment With Retinoids in Patients With Lupus Nephritis

American Journal of Kidney Diseases

Volumn 55, Issue 2, 2010, Pages 344-347

  Kinoshita, Koji ^a   Kishimoto, Kazuya ^a   Shimazu, Hideki ^a   Nozaki, Yuji ^a   Sugiyama, Masafumi ^a   Ikoma, Shinya ^a   Funauchi, Masanori ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Lupus; nephritis; retinoid

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CREATININE; DOUBLE STRANDED DNA ANTIBODY; HEMOGLOBIN; NITROGEN; PREDNISOLONE; PROTEIN; RETINOIC ACID; SERUM ALBUMIN; UREA;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; COMPLEMENT HEMOLYSIS TEST; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG DOSE REDUCTION; ERYTHROCYTE SEDIMENTATION RATE; FACE EDEMA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LABORATORY TEST; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; PERIPHERAL EDEMA; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

ADULT; FEMALE; HUMANS; LUPUS NEPHRITIS; MIDDLE AGED; REMISSION INDUCTION; TRETINOIN;

EID: 74449090066     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.06.012     Document Type: Article

References (19)

1. Walsh S.J., Algert C., Gregorio D.I., Reisine S.T., and Rothfield N.F. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol 22 (1995) 1663-1668
2. Steinberg A.D., and Steinberg S.C. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34 (1991) 945-950
3. Pryor B.D., Bologna S.G., and Kahl L.E. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39 (1996) 1475-1482
4. Baker G.L., Kahl L.E., Zee B.C., Stolzer B.L., Agarwal A.K., and Medsger Jr. T.A. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 83 (1987) 1-9
5. Paillaud E., Costa S., Fages C., et al. Retinoic acid increases proliferation rate of GL-15 glioma cells, involving activation of STAT-3 transcription factor. J Neurosci Res 67 (2002) 670-679
6. Kinoshita K., Yoo B.S., Nozaki Y., et al. Retinoic acid reduces autoimmune renal injury and increases survival in NZB/W F1 mice. J Immunol 170 (2003) 5793-5798
7. Wagner J., Dechow C., Morath C., et al. Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J Am Soc Nephrol 11 (2000) 1479-1487
8. Suzuki A., Ito T., Imai E., et al. Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol 14 (2003) 981-991
9. Oseto S., Moriyama T., Kawada N., et al. Therapeutic effect of all-trans retinoic acid on rats with anti-GBM antibody glomerulonephritis. Kidney Int 64 (2003) 1241-1252
10. Huang M.E., Ye Y.C., Chen S.R., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 (1988) 567-572
11. Ward A., Brogden R.N., Heel R.C., Speight T.M., and Avery G.S. Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders. Drugs 26 (1983) 9-43
12. Peck G.L., Olsen T.G., Butkus D., et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 6 (1982) 735-745
13. Brinckerhoff C.E. Retinoids and rheumatoid arthritis: Modulation of extracellular matrix by controlling expression of collagenase. Methods Enzymol 190 (1990) 175-188
14. Nozaki Y., Yamagata T., Yoo B.S., et al. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice. Clin Exp Immunol 139 (2005) 74-83
15. Morath C., Dechow C., Lehrke I., et al. Effects of retinoids on the TGF-beta system and extracellular matrix in experimental glomerulonephritis. J Am Soc Nephrol 12 (2001) 2300-2309
16. Moreno-Manzano V., Mampaso F., Sepulveda-Munoz J.C., et al. Retinoids as a potential treatment for experimental puromycin-induced nephrosis. Br J Pharmacol 139 (2003) 823-831
17. Datta P.K., and Lianos E.A. Retinoic acids inhibit inducible nitric oxide synthase expression in mesangial cells. Kidney Int 56 (1999) 486-493
18. Schaier M., Jocks T., Grone H.J., Ritz E., and Wagner J. Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol 170 (2003) 1398-1402
19. Pilkington T., and Brogden R.N. Acitretin. A review of its pharmacology and therapeutic use. Drugs 43 (1992) 597-627